Yu Jun Li

Papers

Total Citations

H-Index

About

Yu Jun Li is a leading urologic oncologist whose research focuses on improving outcomes for patients with muscle-invasive bladder cancer (MIBC), with a particular emphasis on refining staging accuracy and treatment strategies. Dr. Li’s major contributions center on identifying clinical and pathological predictors of disease upstaging at radical cystectomy, a critical factor that can determine whether patients receive appropriate neoadjuvant chemotherapy (NAC) or risk undertreatment. In their highly cited 2025 study, Dr. Li demonstrated how staging inaccuracies in MIBC can lead to suboptimal care, and they systematically evaluated predictors of pathologic upstaging stratified by NAC receipt among patients undergoing robot-assisted radical cystectomy. This work has profound implications for personalizing surgical and oncologic decision-making, helping to ensure that patients receive the right intensity of therapy. With over 1,000 citations across their body of work, Dr. Li’s research has been instrumental in advancing the precision of bladder cancer management. Their findings are widely referenced in clinical guidelines and have shaped contemporary approaches to risk stratification, making Dr. Li a respected voice in the field of urologic oncology.